July 2023 OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist: Positive Review from the Drug Safety Monitoring Board (DSMB) on the Ongoing Phase 2 Clinical Trial in Ulcerative Colitis; Positive Opinion for Orphan Drug Designation from the European Medicines Agency in the Treatment of Acute Lymphoblastic Leukemia.
July 2023 OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
June 2023 OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer
June 2023 OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation at International Conferences
June 2023 OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting Tedopi® is the Company’s Most Advanced Product in Clinical Development
May 2023 OSE Immunotherapeutics’ Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director Ahead of the General Shareholders’ Meeting of June 22, 2023
May 2023 OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi® in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIGE 63 trial)
May 2023 OSE Immunotherapeutics to Continue the Clinical Development in Ulcerative Colitis with Full Rights to Lusvertikimab
April 2023 OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update